spacer
home > > summer 2002 > the trials and tribulations of importing clinical trials materials into europe
PUBLICATIONS


The Trials and Tribulations of Importing Clinical Trials Materials into Europe

There are a number of key areas that international pharmaceutical companies will need to consider when planning to conduct clinical studies in Europe. Perhaps most importantly, companies need to be aware of several forthcoming regulatory changes, which will be implemented in the next three years as a result of the adoption of the Clinical Trial Directive (2001/20/EC of the European Parliament and of the Council).

Currently, there is no unified regulation governing the import and movement of material around Europe. Local country regulations apply, which in some countries can be as simple as a notification, while in others a formal application is needed. In the UK, for example, all the details of the study materials would be included in the CTX application.

In general terms, the manufacture of clinical materials is not presently required to comply with GMP, but there are some notable exceptions - Germany, for instance, which applies the same GMP to clinical trial materials (CTM) as to a marketed product.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Keren Winmill, Director of Clinical Trial Supplies at Penn Pharmaceutical Services

Keren Winmill is a Pharmacist with 24 years of experience in the pharmaceutical industry. She joined Penn Pharmaceutical Services in 1990 to manage the clinical supplies unit. Keren spent 12 years with Ciba Geigy in Switzerland and in the UK in regulatory affairs, business development and marketing positions.

Keren subsequently joined Quintiles as Director of Business Development, returning to Penn in 1999 as Director of the Clinical Supplies Business Unit. She is responsible for clinical trial packaging and supply management.

spacer
Keren Winmill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement